Insights into the Role of LncRNAs and miRNAs in Glioma Progression and Their Potential as Novel Therapeutic Targets

SIMPLE SUMMARY: Recent research has revealed the involvement of long non-coding RNAs (lncRNAs) and micro RNAs (miRNAs) in glioma development and advancement, suggesting their potential as biomarkers and therapeutic targets. Late-stage diagnosis and the limited effectiveness of conventional treatments contribute to poor glioma outcomes, highlighting the need for early detection methods. Advances in biotechnology and neuroscience have shed light on non-coding RNAs role in glioma angiogenesis and progression. This review explores the impact of lncRNAs and miRNAs on gene regulation, either promoting or inhibiting glioma progression and establishes connections between these crucial cancer-related molecules. ABSTRACT: Accumulating evidence supports that both long non-coding and micro RNAs (lncRNAs and miRNAs) are implicated in glioma tumorigenesis and progression. Poor outcome of gliomas has been linked to late-stage diagnosis and mostly ineffectiveness of conventional treatment due to low knowledge about the early stage of gliomas, which are not possible to observe with conventional diagnostic approaches. The past few years witnessed a revolutionary advance in biotechnology and neuroscience with the understanding of tumor-related molecules, including non-coding RNAs that are involved in the angiogenesis and progression of glioma cells and thus are used as prognostic biomarkers as well as novel therapeutic targets. The emerging research on lncRNAs and miRNAs highlights their crucial role in glioma progression, offering new insights into the disease. These non-coding RNAs hold significant potential as novel therapeutic targets, paving the way for innovative treatment approaches against glioma. This review encompasses a comprehensive discussion about the role of lncRNAs and miRNAs in gene regulation that is responsible for the promotion or the inhibition of glioma progression and collects the existing links between these key cancer-related molecules.